Qlife announced on 22 April that a research agreement had been made with Nordsjällands Hospital (NOH), for continued validation of the COVID-19 test.
Presentation of Qlife on Stora Aktiedagen (Shareholder’s Day)
CEO Thomas Warthoe will present Qlife at Stora Aktiedagen (Shareholder’s Day) in Gothenburg on 4 November and in Stockholm on 25 November. Would you like to read more about the programme and how to sign up, see attached notification.
Resolution on adoption of accounts and allocation of the company’s result
FINANCIAL SUMMARY FIRST QUARTER 2020
The parties have agreed a testing plan for all players, judges and club staff for Covid-19 in the professional leagues (3F SuperLiga and NordicBet Liga).
Qlife announces that it has entered into a research agreement with Nordsjællands Hospital (NOH), to continue the validation of the Egoo Sars-CoV-2 virus test.
Information regarding the coronavirus
Due to increased requests for information on route to market for Qlife’s COVID-19 test the company is updating the following:
Qlife announces that it has closed a license and supply agreement with Aidian Oy to access and incorporate their patented SIBA® Technology into the Egoo.Health platform.
Qlife went public on March 2 with a clear strategy for the next year, that strategy is still being followed and we do not see any large obstacles to it due to the Corona virus outbreak.